Stockscreener 앱 받기
101.35
3.48%
-3.65
전일 마감가:
$105.00
열려 있는:
$108.01
하루 거래량:
8.59M
Relative Volume:
3.46
시가총액:
$21.97B
수익:
$606.42M
순이익/손실:
$-1.28B
주가수익비율:
-15.83
EPS:
-6.403
순현금흐름:
$-997.58M
1주 성능:
-23.95%
1개월 성능:
-36.73%
6개월 성능:
-46.57%
1년 성능:
+54.43%
1일 변동 폭
$98.98
$108.63
1주일 범위
$98.98
$142.90
52주 변동 폭
$64.84
$212.75
Insmed Inc Stock (INSM) Company Profile
명칭
Insmed Inc
전화
908-977-9900
주소
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
101.35 | 21.97B | 606.42M | -1.28B | -997.58M | -6.403 |
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 109.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
714.89 | 74.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.17 | 48.64B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.05 | 39.39B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
312.12 | 32.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Raymond James | Outperform |
| 2026-03-30 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2026-03-16 | 재개 | Jefferies | Buy |
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2026-01-23 | 개시 | Roth Capital | Buy |
| 2025-12-19 | 재개 | Truist | Buy |
| 2025-12-04 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-10-28 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-08-20 | 개시 | William Blair | Outperform |
| 2025-08-13 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | 개시 | Jefferies | Buy |
| 2025-02-25 | 개시 | RBC Capital Mkts | Outperform |
| 2024-04-23 | 개시 | Truist | Buy |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-07-26 | 개시 | Guggenheim | Buy |
| 2022-12-09 | 개시 | Mizuho | Buy |
| 2022-12-07 | 개시 | Barclays | Overweight |
| 2022-11-18 | 개시 | BofA Securities | Buy |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2021-12-06 | 개시 | JP Morgan | Overweight |
| 2021-10-19 | 재개 | Monness Crespi & Hardt | Buy |
| 2021-10-19 | 재개 | Morgan Stanley | Overweight |
| 2021-10-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-10-12 | 재개 | Stifel | Buy |
| 2019-09-03 | 개시 | Goldman | Buy |
| 2019-04-09 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-15 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-01-02 | 개시 | Canaccord Genuity | Buy |
| 2018-08-06 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | 개시 | Goldman | Neutral |
| 2018-04-23 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | 개시 | Morgan Stanley | Overweight |
| 2018-01-18 | 개시 | Credit Suisse | Neutral |
| 2017-09-05 | 재확인 | Evercore ISI | Outperform |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-07-11 | 개시 | Robert W. Baird | Outperform |
| 2016-03-15 | 개시 | Stifel | Buy |
| 2015-11-09 | 다운그레이드 | UBS | Buy → Neutral |
| 2015-10-06 | 재확인 | H.C. Wainwright | Buy |
| 2015-06-09 | 개시 | Citigroup | Neutral |
| 2014-03-26 | 재확인 | HC Wainwright | Buy |
모두보기
Insmed Inc 주식(INSM)의 최신 뉴스
Here's What Analysts Are Forecasting For Insmed Incorporated (NASDAQ:INSM) After Its First-Quarter Results - Yahoo! Finance Canada
Insmed (INSM) Q1 2026 Revenue Surge Tests Profitability Narrative - simplywall.st
Insmed (INSM) Post-Earnings Selloff Seen as Buying Opportunity - GuruFocus
INSM Maintained by RBC Capital -- Price Target Lowered to $205 - GuruFocus
INSM Maintained by Wells Fargo -- Price Target Lowered to $160 - GuruFocus
Insmed Stock Sell-off is Overdone as Underlying Metrics Appear Positive, RBC Says - marketscreener.com
RBC Cuts Price Target on Insmed to $205 From $220, Keeps Outperform Rating - marketscreener.com
Insmed's Q1 earnings beat, sales miss estimates, stock tanks 23% - MSN
INSM Maintains by Guggenheim -- Price Target Lowered to $226 - GuruFocus
A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $160 to $243 - Moomoo
Insmed's Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23% - Yahoo Finance
Insmed’s 44% decline validates InvestingPro’s overvalued call By Investing.com - Investing.com
Insmed Q1 Earnings Call Highlights - Yahoo Finance
TD Cowen Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $243 - Moomoo
Insmed Earnings Call Highlights BRINSUPRI-Driven Momentum - TipRanks
Insmed's Blockbuster Drug Brinsupri Drives Record Revenue, Yet Shares Tumble - AD HOC NEWS
Insmed (INSM) Q1 2026 Earnings Transcript - The Globe and Mail
Roth MKM Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $212 - Moomoo
Insmed Incorporated Q1 2026 Earnings Call Summary - Yahoo Finance
Insmed Bronchiectasis Push With Ty Pennington May Expand Therapy Opportunity - simplywall.st
U.S. Indexes Closed Down Thursday; Insmed Fell Furthest - Barron's
Insmed reiterates BRINSUPRI at least $1B 2026 revenue target while targeting ARIKAYCE label expansion in H1 2027 - MSN
Biotech Tanks On Its Biggest Launch; Why Analysts Are Bullish - Investor's Business Daily
Insmed Down Over 21%, Worst Performer in the Nasdaq 100 So Far Today -- Data Talk - Moomoo
Insmed Q1 2026 slides: BRINSUPRI surges 44%, ARIKAYCE expansion ahead - Investing.com
Earnings call transcript: Insmed Q1 2026 beats forecasts but stock tumbles - Investing.com
Nasdaq 100 Climbs Records, Oil Extends Drop As Iran Weighs Hormuz Deal: Stock Market Today - Benzinga
William Blair Maintains Insmed(INSM.US) With Buy Rating - Moomoo
IBD: Insmed Tanks On Its Most Important Launch; Why Analysts Remain Bullish - Moomoo
Why is Insmed stock sliding today? - Investing.com
Why is Insmed stock sliding today? By Investing.com - Investing.com Canada
Insmed Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Insmed Inc Stock Warning Signs - GuruFocus
Insmed Q1 Loss Narrows, Revenue Rises; Shares Down Pre-Bell - Moomoo
Insmed reports new cathepsin C inhibitors - BioWorld News
Insmed (INSM) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Insmed (NASDAQ:INSM) Q1 Revenue Miss Triggers Pre-Market Slide Despite Narrower Loss - ChartMill
Insmed stock falls 6% on Q1 beat as investors eye guidance By Investing.com - Investing.com UK
Q1 2026 Insmed Inc Earnings Call Transcript - GuruFocus
Earnings Flash (INSM) Insmed Incorporated Reports Q1 Revenue $306.0M, vs. FactSet Est of $300.8M - marketscreener.com
Earnings Flash (INSM) Insmed Posts Q1 Net Product Revenue $306M, vs. FactSet Est of $300.8M - marketscreener.com
Earnings Flash (INSM) Insmed Posts Q1 Loss $0.76 a Share, vs. FactSet Est of $0.96 Loss - marketscreener.com
INSMED ($INSM) Releases Q1 2026 Earnings - Quiver Quantitative
Insmed: Q1 Earnings Snapshot - marketscreener.com
Insmed Q1 revenue jumps 230%, net loss narrows - TradingView
INSMED Inc 1Q 2026: Revenue $306M, EPS $(0.76) — 10-Q Summary - TradingView
Earnings Flash (INSM) Insmed Posts Q1 Loss $0.76 a Share, Vs. FactSet Est of $0.96 Loss - Moomoo
Insmed (NASDAQ: INSM) posts $306M Q1 sales, reiterates 2026 outlook - Stock Titan
BRINSUPRI launch powers Insmed (INSM) Q1 2026 revenue surge despite net loss - Stock Titan
Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update - PR Newswire
Insmed CEO William Lewis sells $1.47m in company stock By Investing.com - Investing.com India
Insmed Inc (INSM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Insmed Inc 주식 (INSM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Lewis William | Chair and CEO |
May 04 '26 |
Sale |
137.34 |
10,699 |
1,469,442 |
301,185 |
11.97%
0.49%
자본화:
|
볼륨(24시간):